The Texas Liver Institute

San Antonio, Texas 78229

2 studies enrolling now · 29 studies all time

What they study most

Alpha1-Antitrypsin Deficiency, Autoimmune Hepatitis, Bile Duct Stricture, Biliary Tract Diseases, Cholangitis, Cholestasis, Chronic HBV Infection, Digestive System Diseases, Healthy, Healthy Volunteer, Healthy Volunteers, Hepatic Cirrhosis

Studies at this site

• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Recruiting now
• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein — Recruiting now
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Running, not enrolling
• A Varegacestat Hepatic Impairment Study — Completed
• A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants — Completed
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants — Completed
• Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis — Completed
• A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment — Completed
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection — Stopped early
• Phase 2b Study in NASH to Assess IVA337 — Completed
• A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod — Completed
• A Study of JNJ-53718678 in Participants With Hepatic Impairment — Stopped early
• A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C — Completed
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis — Stopped early
• A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) — Completed
• A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment — Completed
• The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology — Stopped early
• A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants — Stopped early
• A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease — Completed
• Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects — Completed
• A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects — Completed
• Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies — Completed
• Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function — Completed
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C — Completed
• Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing — Completed